サンプル依頼リスト カート
  • English
  • Korean
表紙：大うつ病性障害の世界市場-2023年～2030年
市場調査レポート
商品コード
1374838

大うつ病性障害の世界市場-2023年～2030年

Global Major Depressive Disorder Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 185 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.90円
大うつ病性障害の世界市場-2023年～2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 185 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

大うつ病性障害（MDD）はうつ病とも呼ばれ、世界中で最も重篤かつ一般的な精神疾患の一つです。持続的な悲しみ、興味や喜びの喪失、気力の低下、食欲や睡眠の悪化、さらには自殺を特徴とし、日常活動や心理社会的機能を障害します。

MDDは気分の落ち込みを特徴とする病態であり、遺伝、ストレス、ホルモンバランスの乱れ、アルコールや薬物の使用、特定の病状、特定の薬物、小児期の虐待など、さまざまな要因によって引き起こされる可能性があります。正確な原因は不明ですが、これらの要因はMDD発症のリスクを高める可能性があります。

市場力学：市場促進要因と市場抑制要因

治療選択肢における技術的進歩の台頭

過去20年の間に、大うつ病性障害（MDD）の治療法において大きな進歩が生じています。うつ病は個人差があることが認識されるようになり、それに応じて治療を調整するために、個人の神経化学的不均衡を特定・診断する努力がなされています。

エビデンスに基づく治療、特に薬物療法において進歩がみられます。シタロプラム、エスシタロプラム、フルオキセチン、セルトラリンなど、より選択的で特殊な抗うつ薬が開発され、有効性が向上し、副作用が少なくなっています。薬物療法と心理療法、特に認知行動療法や精神力動療法を組み合わせることが最も効果的なアプローチであることが示されています。

例えば、慢性疼痛、精神科、てんかん、末梢神経系および中枢神経系のその他の疾患におけるアンメットニーズに対応するため、神経細胞興奮性障害の新規治療法の開発に注力する臨床段階のバイオテクノロジー企業であるEliem Therapeutics, Inc.は、ETX-155臨床プログラムの推進計画に関する最新情報を提供しました。

さらに、ライフスタイルの変化によるワークライフバランスの乱れ、MDD患者数の増加が、予測期間中のMDD治療市場を牽引すると予想される主な要因となっています。また、世界中の製薬メーカーによるMDD治療薬の共同開発・共同販売のための提携、新薬の開発、政府の適切な償還政策なども、MDD治療薬市場の成長を後押ししています。

市場力学：市場抑制要因

大うつ病性障害（MDD）は、うつ病以上の症状を引き起こす可能性があります。健康に影響を及ぼし、考え方や行動を変えるような合併症を引き起こすこともあります。合併症には、体重増加や肥満、慢性疾患、慢性疼痛、自傷行為、認知機能の変化などがあります。

しかし、新薬承認のために様々な政府が課す厳しい規制、いくつかのブロックバスター薬の特許満了、他の薬との合併症のリスク、大うつ病性障害治療薬の関連副作用などが、予測期間における大うつ病性障害治療薬市場の成長を妨げています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 治療選択肢における技術進歩の高まり
    • 抑制要因
      • 疾患に伴う合併症
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMIの見解

第6章 COVID-19分析

第7章 薬剤タイプ別

  • 抗うつ薬
  • 非定型抗うつ薬
  • 抗精神病薬
  • 神経調節薬

第8章 投与経路別

  • 経口
  • 静脈内
  • 非経口

第9章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Eli Lilly and Company
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Allergan
  • Alkermes
  • Lundbeck
  • Johnson & Johnson
  • Pfizer, Inc
  • AstraZeneca plc
  • Merck & Co
  • GlaxoSmithKline plc
  • Sanofi S.A
  • Takeda Pharmaceutical Company Limited（*LIST NOT EXHAUSTIVE）

第13章 付録

目次
Product Code: PH7379

Overview

Major depressive disorder (MDD) also referred to as depression, is one of the most severe and common psychiatric disorders across the world. It is characterized by persistent sadness, loss of interest or pleasure, low energy, worse appetite and sleep, and even suicide, disrupting daily activities and psychosocial functions.

MDD is a condition characterized by mood swings, which can be triggered by various factors such as genetics, stress, hormone imbalance, alcohol or drug use, certain medical conditions, specific medications, and childhood abuse. The exact cause is unknown, but these factors can increase the risk of developing MDD.

Market Dynamics: Drivers and Restraints

Rise in technological advancements in treatment options

Over the past two decades, significant progress has been made in the treatment options for major depressive disorder (MDD). It is now recognized that depression varies from person to person, and efforts are being made to identify and diagnose the specific neurochemical imbalances in individuals to tailor treatment accordingly.

Advances have been made in evidence-based treatments, particularly in drug therapy. More selective and specialized antidepressants, such as citalopram, escitalopram, fluoxetine, and sertraline, have been developed, offering improved efficacy and fewer side effects. Combining drug therapy with psychotherapy, specifically cognitive-behavioral and psychodynamic therapy, has been shown to be the most effective approach.

For instance, Eliem Therapeutics, Inc a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, provided an update on its plans to advance its ETX-155 clinical program.

Furthermore, Work life imbalances due to lifestyle changes, and an increase in the MDD patient pool are the key drivers expected to drive the MDD treatment market over the forecasted period. Partnerships for co-development and co-marketing of MDD drugs among drug manufacturers across the globe, the development of new drugs, and adequate government reimbursement policies have also fueled the growth of the MDD treatment market.

Market Dynamics: Restraint

Major depressive disorder (MDD) can cause more than depression. It can lead to complications that affect your health and change how you think and behave. Some of the complications include weight gain and obesity, chronic illness, chronic pain, self-harm, cognitive changes and others.

However, stringent regulations imposed by various governments for new drug approval, patent expiries of some blockbuster drugs, risk of complications with other medications, and related side effects of major depressive disorder drugs hamper the growth of the major depressive disorder treatment market over the forecasted period.

Segment Analysis

The global major depressive disorder is segmented based on drug type, route of administration, distribution channel and region.

The Antidepressants from the drug type segment accounted for approximately 41.2 % of the market share

The Antidepressants from the drug type segment accounted for approximately 41.2 % and it is expected to be dominated during the forecast period. Antidepressants are psychiatric drugs which are licensed to treat depression. Some are also licensed to treat other conditions, such as anxiety disorders phobias, bulimia (an eating disorder), and some physical conditions, including managing long-term pain.

For instance, in December 2022 AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved VRAYLAR (cariprazine) as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults. Supported by clinical data demonstrating efficacy and well-established tolerability, this additional indication provides a new option for adults who have a partial response to the treatment of an antidepressant.

Moreover, in September 2022 Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced positive results from a phase III clinical trial in Japan of brexpiprazole in the treatment of major depressive disorder. The late-stage trial evaluated the efficacy and safety of brexpiprazole as adjunctive therapy in 740 adult patients in Japan, aged 20 to 64 years, with major depressive disorder. Brexpiprazole was administered once daily for six weeks, in 1 mg or 2 mg doses, as an adjunctive therapy to SSRI or SNRI antidepressants, for patients who previously had inadequate responses to antidepressant monotherapy.

Geographical Analysis

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4 % of the total market share throughout the forecast period, owing to an increase in the number of patients suffering from major depressive disorder, advancement in technology to develop new therapeutic drugs, rise in the ongoing clinical trials, advanced healthcare infrastructure and among others are expected to dominate by this region during the forecast period.

For instance, according to clinicaltrails.gov in September 2022 Janssen Research & Development, LLC started clinical studies on a Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT) which is under phase 3 with 840 active participants have been enrolled and these studies have been going in Alabama United states.

Moreover, according to clinicaltrails.gov on November 2022 Otsuka Pharmaceutical Development & Commercialization, Inc started a clinical study on a Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder which is under Phase 3 with 900 enrolled participants and this studies currently going in New York United States.

COVID-19 Impact Analysis

COVID-19 had a substantial impact on major depressive disorder where according to studies published on the Impact of the COVID-19 pandemic on major depressive disorder in acute psychiatric inpatients where the studies focused on the relationship between COVID-19 and mental disorders reported results similar to those summarized above about psychiatric symptoms in the general population.

In particular, a large systematic review and meta-analysis found an increase of 27.6% in the prevalence of major depressive disorder (MDD) after the outbreak of the COVID-19 pandemic (COVID-19 Mental Disorders Collaborators, 2021) with a peak of the incidence from March to May 2020 in conjunction with the first restriction measures.

Market Segmentation

By Drug Type

  • Antidepressants
    • Selective Serotonin Reuptake Inhibitors (SSRIs)
    • Dopamine Norepinephrine Reuptake Inhibitor
    • Serotonin Norepinephrine Reuptake Inhibitor
    • Serotonin Modulators
    • Monoamine oxidase inhibitors (MAOIs)
    • Others
  • Atypical Antidepressants
  • Antipsychotics
  • Neuromodulators

By Route of Administration

  • Oral
  • Intravenous
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in the major depressive disorder market include: Eli Lilly and Company, Allergan, Alkermes, Lundbeck, Johnson & Johnson, Pfizer, Inc, AstraZeneca plc, Merck & Co, GlaxoSmithKline plc, Sanofi S.A and among others.

Key Developments

  • In September 2023 Relmada Therapeutics, Inc., a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced efficacy results for the de novo (or new to treatment) patients (204 patients) and safety results for all subjects (627 patients) from the Phase 3, long-term, open-label, registrational trial (Study 310) of REL-1017 in patients with Major Depressive Disorder (MDD).
  • In August 2023 Biogen Inc. and Sage Therapeutics, Inc announced the U.S. Food and Drug Administration (FDA) approved ZURZUVAE (zuranolone) 50 mg for adults with postpartum depression (PPD). ZURZUVAE is the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms for women with PPD.
  • In May 2023 - BioXcel Therapeutics, Inc., a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, announced positive top-line data from its Phase 1b multiple ascending dose (MAD) trial of BXCL501 (dexmedetomidine) sublingual film.

Why Purchase the Report?

  • To visualize the global major depressive disorder market segmentation based on drug type, route of administration, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous major depressive disorder market-level data points with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global major depressive disorder market report would provide approximately 69 tables, 70 figures, and 185 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Type
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Driver
      • 4.1.1.1. Rise in technological advancements in treatment options
    • 4.1.2. Restraints
      • 4.1.2.1. Complications associated with the disease
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 7.1.2. Market Attractiveness Index, By Drug Type
  • 7.2. Antidepressants*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Atypical Antidepressants
  • 7.4. Antipsychotics
  • 7.5. Neuromodulators

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Intravenous
  • 8.4. Parenteral

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. UK
      • 10.3.7.3. France
      • 10.3.7.4. Italy
      • 10.3.7.5. Spain
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.5.1. China
      • 10.5.5.2. India
      • 10.5.5.3. Japan
      • 10.5.5.4. Australia
      • 10.5.5.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Eli Lilly and Company
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Allergan
  • 12.3. Alkermes
  • 12.4. Lundbeck
  • 12.5. Johnson & Johnson
  • 12.6. Pfizer, Inc
  • 12.7. AstraZeneca plc
  • 12.8. Merck & Co
  • 12.9. GlaxoSmithKline plc
  • 12.10. Sanofi S.A
  • 12.11. Takeda Pharmaceutical Company Limited (*LIST NOT EXHAUSTIVE)

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us